Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the first participant has been enrolled in ZUPREME-2, a phase ...

Roche's move for the asset comes shortly after Zealand started the phase 2b ZUPREME-1 trial of petrelintide in people overweight or obese, and ahead of the ZUPREME-2 study in overweight or obese ...

–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ...

At close: 8:00:34 AM GMT+2 Loading Chart for 22Z.F ...